The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.
Stephen Todd Pisle
No relevant relationships to disclose
Heather M Pressler
No relevant relationships to disclose
Sarah M Troutman
No relevant relationships to disclose
Joel Robert Eisner
Employment or Leadership Position - Viamet Pharmaceuticals
Stephen W Rafferty
Employment or Leadership Position - Viamet Pharmaceuticals
Robert J Schotzinger
Employment or Leadership Position - Viamet Pharmaceuticals
William R Moore
Employment or Leadership Position - Viamet Pharmaceuticals
William Douglas Figg
No relevant relationships to disclose